-
Mashup Score: 0
The incidence and severity of SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases on immunosuppressants was similar to that in controls. However, caution might still be warranted for those on anti-CD20 therapy and those with traditional risk factors.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 4Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis - 2 year(s) ago
An attenuated response to SARS-CoV-2 vaccination has been observed in several immunosuppressed populations.1,2 Among patients with rheumatic diseases, the use of lymphocyte depleting therapies, such as mycophenolate mofetil and rituximab, have been associated with reduced rates of seroconversion.2 Mycophenolate mofetil is the mainstay of immunosuppressant therapy for patients with systemic…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW Comment by @RachelWallwork and colleagues @jhrheumatology—Effect of #mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with #SystemicSclerosis https://t.co/JSEc06KrJ9 #LancetRheumatology @JuliePaikMD @CaoilfhionnMD https://t.co/1HHX0Njmhw
-
-
Mashup Score: 0
Significant improvements in disease activity metrics of rheumatoid arthritis with ABBV-599 were driven by the JAK inhibitor upadacitinib with no discernible effect by the BTK inhibitor elsubrutinib.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW RESEARCH—Safety and efficacy of elsubrutinib (BTK inhibitor) or #upadacitinib alone or in combination in patients with #rheumatoidarthritis: a multicentre, double-blind, randomised, controlled, phase 2 trial https://t.co/uidCOGDRxq #LancetRheumatology https://t.co/lZDz8gGXiS
-
-
Mashup Score: 0Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding? - 2 year(s) ago
Despite the high reported prevalence and burden of cognitive dysfunction in systemic lupus erythematosus (SLE), there is poor understanding of its aetiology, clinical assessment, and management. In part, this lack of understanding is due to conceptual disorganisation in the available literature. In this Review, we address key knowledge gaps in the nomenclature, assessment, and interpretation of…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
ICYMI, the inspiration for our April cover—@Sudha_Raghunath and colleagues review our current understanding of cognitive dysfunction in systemic #lupus erythematosus https://t.co/cBmjJUIBrU #SLE #LancetRheumatology https://t.co/39v9DhH4ND
-
-
Mashup Score: 6
Two vaccine doses were found to be highly effective against both SARS-CoV-2 infection and severe COVID-19 outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease during the study period. Research is needed to determine the durability of effectiveness of three doses over time, particularly against emerging variants.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW RESEARCH—Population-based study from Ontario, Canada, shows that mRNA vaccines are highly effective against both #SARSCoV2 infection and severe #COVID19 outcomes in patients with immune-mediated inflammatory diseases https://t.co/NbIiEnDmxy #LancetRheumatology @GovCanHealth https://t.co/719EXL2mcJ
-
-
Mashup Score: 0
For more than a decade the concept of treat-to-target has become accepted as a treatment strategy for people with inflammatory arthritis. The benefit of tight control was first seen in the Tight Control of Rheumatoid Arthritis (TICORA) study in 2009 before the availability of biologics.1 In 2015, the Tight Control of Psoriatic Arthritis (TICOPA) study confirmed the benefit of treat-to-target in…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW Correspondence—@DrLauraCoates and colleagues show that treat-to-target in #PsoriaticArthritis is cost-effective in the #biosimilar era https://t.co/xnRcdiCvKh #LancetRheumatology @NICEComms https://t.co/kU0ismLP6E
-
-
Mashup Score: 2Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune-mediated inflammatory diseases - 2 year(s) ago
Patients with immune-mediated inflammatory diseases are at a higher risk of severe COVID-19, in part, due to immune suppression induced by treatment.1,2 France began vaccinations against COVID-19 in December, 2020, and patients with immune-mediated inflammatory diseases receiving immunosuppressive drugs were prioritised for vaccination.3 It has since been demonstrated that patients with…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW—Pre-exposure anti-SARS-CoV-2 monoclonal antibodies in severely immunocompromised patients with immune mediated inflammatory diseases https://t.co/YAZjfsqsn9 #LancetRheumatology https://t.co/Sv5z6lmIXI
-
-
Mashup Score: 0Research in Brief - 2 year(s) ago
David Jayne and colleagues conducted a phase 2 trial to assess the safety and efficacy of the type I interferon receptor inhibitor anifrolumab in patients with active lupus nephritis. 147 patients were randomly assigned (1:1:1) to receive 300 mg intravenous anifrolumab (the basic regimen), an intensified anifrolumab regimen consisting of three 900 mg doses followed by 300 mg thereafter, or…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
April Research in Brief featuring #lupus #nephritis, #polymyalgia rheumatica, #osteoarthritis, and more! https://t.co/kQ6xl3Pl9y #LancetRheumatology https://t.co/3T7o5koZfT
-
-
Mashup Score: 5
Ruxolitinib 5 mg twice per day showed no benefit in the overall study population. A larger sample is required to determine the clinical importance of trends for increased efficacy in patient subgroups.
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
@meilan_han @sinisauksav No perfect therapy for the imperfect #COVID19 #cytokinestorm Linked Comment by Randy Q Cron @ChildrensAL https://t.co/0sqRrqayIL https://t.co/FOCcMnTz68
-
NEW RESEARCH—Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with #COVID19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/0sqRrqayIL #LancetRheumatology @meilan_han @sinisauksav https://t.co/YFdnxMKRlH
-
-
Mashup Score: 1Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases - 2 year(s) ago
Many immunosuppressed patients with rheumatic and musculoskeletal disease have a poor antibody response to two-dose SARS-COV-2 mRNA vaccination,1,2 prompting widescale authorisation of a third vaccine dose for these patients. High antibody concentrations are required to overcome immune evasion by variants of concern in immunocompetent patients,3 and although a third dose augments the immune…
Source: The Lancet RheumatologyCategories: Latest Headlines, RheumatologyTweet-
NEW COMMENT—Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases https://t.co/hBG6jl7qx0 #LancetRheumatology @HopkinsMedicine https://t.co/dTwfHqHSN0
-
NEW RESEARCH—Clinical and humoral determinants of #SARSCoV2 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases using #immunosuppressants https://t.co/FaSR9eBIg5 #LancetRheumatology https://t.co/jF04vUcxQ0